Login to Your Account

Clinic Roundup

Wednesday, January 23, 2013
• Axelar AB, of Stockholm, Sweden, a Karolinksa Development AB portfolio firm, said an investigator-sponsored Phase I/II study started in the U.S. to test AXL1717, an oral small-molecule insulin-like growth factor 1 receptor inhibitor, in patients with malignant astrocytomas, a type of brain tumor.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription